OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its third
quarter 2009 financial results will be released on October 21, 2009,
after the markets close. Following the announcement, OSI’s management
will host a live conference call and webcast at 5:00p.m. Eastern Time to
review the Company’s financial results, product portfolio and business
developments.
To access the live webcast or the archive via the Internet, log on to www.osip.com.
Please connect to the Company's website at least 15 minutes prior to the
conference call to ensure adequate time for any software download that
may be needed to access the webcast. Alternatively, please call
1-888-401-4689 (U.S.) or 1-719-457-2698 (international) to listen to the
call. The conference ID number for the live call is 9702946. Telephone
replay is available approximately two hours after the call. To access
the replay, please call 1-888-203-1112 (U.S.) or 1-719-457-0820
(international). The conference ID number is 9702946.
About OSI Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and changing
lives" by discovering, developing and commercializing high-quality,
novel and differentiated targeted medicines designed to extend life and
improve the quality of life for patients with cancer and
diabetes/obesity. For additional information about OSI, please visit http://www.osip.com.
This news release contains forward-looking statements. These
statements are subject to known and unknown risks and uncertainties that
may cause actual future experience and results to differ materially from
the statements made.
Factors that might cause such a difference
include, among others, OSI's and its collaborators' abilities to
effectively market and sell Tarceva and to expand the approved
indications for Tarceva, OSI’s ability to protect its intellectual
property rights, safety concerns regarding Tarceva,
competition
to Tarceva and OSI’s drug candidates
from other biotechnology and
pharmaceutical companies, the completion of clinical trials, the
effects of FDA and other governmental regulation, including pricing
controls,
OSI's ability to successfully develop and commercialize
drug candidates, and other factors described in OSI Pharmaceuticals'
filings with the Securities and Exchange Commission.
